Dow 23,000 Buoyed By United Health & Johnson & Johnson

01:58 10/17/2017

Despite the losses in industrial, financial and tech stocks, The Dow 23,000 is a breath of fresh air for investors across the board.

Here are some of the most active stocks today.

Neothetics, Inc.NEOT  – Shares rally on heavy volume after news on merger agreement with Evofem Biosciences Inc. The merger will position the combined company with an opportunity to become a leading women’s health company that develops and commercializes novel products. Upon closing of the transaction, Neothetics will be renamed Evofem Biosciences, Inc., and will be under the leadership of Evofem Biosciences’ Chief Executive Officer, Saundra Pelletier. Neothetics, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutics for the aesthetic market. Its lead product candidate is LIPO-202, an injectable formulation of salmeterol xinafoate for the reduction of localized fat deposits under the chin, or submental fat, as well as for reduction of central abdominal bulging due to subcutaneous fat in non-obese patients.

TransEnterix, Inc. TRXC  – Continued its rally today printing an intraday high of $5 on even strong volume than yesterday. The last hour of trading could see a stronger push shattering the intraday high. TransEnterix is a medical device company that is pioneering the use of robotics to improve minimally invasive surgery by addressing the clinical and economic challenges associated with current laparoscopic and robotic options.

Diffusion Pharmaceuticals Inc. DFFN  - shares of Diffusion Pharmaceuticals opened with a gap up after announcing that it Received Final FDA Protocol Guidance for Phase 3 Clinical Trial with TSC in Patients Newly Diagnosed with Inoperable Glioblastoma Multiforme. Diffusion Pharmaceuticals Inc., a clinical-stage biotechnology company, developing small-molecule drugs that help regulate the movement of oxygen into tissue by a novel mechanism of action. Its lead product candidate is trans sodium crocetinate, which is in Phase I/II clinical trials for the treatment of glioblastoma multiforme (GBM); Phase II clinical trials for the treatment of pancreatic cancer; and Phase II/III clinical trials for the treatment of metastatic brain cancer.

This article has been provided by a Chasing Markets contributor. All content submitted by this author represent their personal opinions, and should be considered as such for entertainment purpose only. All opinions expressed are those of the writer, and may not necessarily represent fact, opinions, or bias of Chasing Markets.
Most Read